Skip to content

LivaNova LIVN Retained Earnings

Retained Earnings at other companies

Abbott logo
AbbottABT
$49.96B+4.7%
Haemonetics logo
HaemoneticsHAE
$279.34M-20.7%
Medtronic logo
MedtronicMDT
$32.64B+3.7%
ITG
Integer HoldingsITGR
$1.01B+16.3%
ResMed logo
ResMedRMD
$6.96B+20.4%
Boston Scientific logo
Boston ScientificBSX
$6.91B+107%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's retained earnings?
LivaNova (LIVN) reported retained earnings of -$1.12B in Q1 2026.
How has LivaNova's retained earnings changed year-over-year?
LivaNova's retained earnings increased by 8.7% year-over-year, from -$1.23B to -$1.12B.
What is the long-term trend for LivaNova's retained earnings?
Over 5 years (2020 to 2025), LivaNova's retained earnings has grown at a 8.5% compound annual growth rate (CAGR), from -$761.97M to -$1.15B.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.